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Gastroesophageal reflux disease (GERD), mainly characterized by heartburn or regurgitation, 
is a common condition in the Western world with an increasing prevalence. GERD is 
associated with an increased risk of adenocarcinoma of the esophagus, and possibly of supra-
esophageal cancers of the larynx, pharynx and lung. GERD is typically treated with antireflux 
medication, mainly proton pump inhibitors, but an alternative is antireflux surgery with 
fundoplication. The present thesis aimed to assess outcomes of antireflux surgery with 
regards to supra-esophageal cancer risk and mortality by conducting multinational 
population-based cohort studies using the Nordic antireflux surgery cohort (NordASCo), 
which includes all adult individuals with a documented diagnosis of GERD or antireflux 
surgery procedure in the national patient registries in any of the five Nordic countries from 
year 1980 to 2014. 
Study I and II investigated whether antireflux surgery decreases the risk of laryngeal and 
pharyngeal squamous cell carcinoma (Study I) and the risk of small cell carcinoma, 
squamous cell carcinoma and adenocarcinoma of the lung (Study II) in NordASCo. We 
calculated standardized incidence ratios (SIR) and hazard ratios (HR) with 95% confidence 
intervals (CI). The overall risk of laryngeal or pharyngeal squamous cell carcinoma were 
decreased (SIR 0.62 [95% CI 0.44-0.85] and HR 0.55 [95% CI 0.38-0.80]), and the point 
estimates decreased further >10 years after surgery. The SIRs and HRs of laryngeal 
squamous cell carcinoma showed a particular decrease >10 years after surgery (SIR 0.28 
[95% CI 0.08-0.72] and HR 0.23 [95% CI 0.08-0.69]). Regarding lung cancer, the overall 
risk was below unity for small cell (SIR 0.57 [95% CI 0.41-0.77] and HR 0.63 [95% CI 0.44-
0.90]) and squamous cell carcinoma (SIR 0.75 [95% CI 0.60-0.92] and HR 0.80 [95% CI 
0.62-1.03]), but not for adenocarcinoma (SIR 0.90 [95% CI 0.76-1.06] and HR 1.03 [95% CI 
0.84-1.26]). 
Study III examined all-cause and disease-specific mortality after antireflux surgery versus 
antireflux medication in patients with reflux esophagitis or Barrett’s esophagus in NordASCo 
(except for Norway). Compared to antireflux medication, the HRs of mortality from all 
causes (HR 0.61, 95% CI 0.58-0.63), cardiovascular disease (HR 0.58, 95% CI 0.55-0.61), 
respiratory disease (HR 0.62, 95% CI 0.57-0.66), laryngeal or pharyngeal cancer (HR 0.35, 
95% CI 0.19-0.65), and lung cancer (HR 0.67, 95% CI 0.58-0.80) were decreased, while 
mortality from esophageal cancer (HR 1.05, 95% CI 0.87-1.28) was not, after antireflux 
surgery. 
Study IV assessed absolute rates and risk factors of poor short-term outcomes following 
primary laparoscopic and secondary antireflux surgery by using an updated version of 
NordASCo with the study period 2000-2018. The absolute risk of 90-day mortality and 90-
day reoperation was 0.13% and 3.0%, respectively, after primary laparoscopic antireflux 
surgery, and 0.19% and 6.2%, respectively, after secondary antireflux surgery. Risk estimates 
of 90-day mortality were increased with higher age and greater comorbidity, and reduced 
with higher hospital volume, after primary surgery. Risk estimates of 90-day reoperation 
were increased with greater comorbidity after primary and secondary surgery. Risk estimates 
of prolonged hospital stay were increased with higher age and comorbidity after both primary 
and secondary surgery, and were decreased with higher hospital volume after primary 
surgery. 
In conclusion, antireflux surgery seems to decrease the risk of laryngeal and pharyngeal 
cancer, as well as small cell carcinoma and squamous cell carcinoma of the lung, and may 
also decrease the risk of all-cause mortality, and has a favorable safety profile, particularly in 
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Gastroesofageal reflux disease (GERD), characterized by symptoms of heartburn and 
regurgitation, affects up to 28% of adults in the world, with a seemingly increasing 
prevalence in the past two to three decades. While GERD symptoms can affect quality of life 
and can lead to complications, it is considered a benign disease. Nonetheless, GERD 
increases the relative risk of esophageal adenocarcinoma, and might also increase the risk of 
cancer in the larynx, pharynx and lung. GERD is mainly treated with antireflux medication, 
but antireflux surgery is an alternative option. 
The focus of the present thesis is on antireflux surgery in relation to supra-esophageal cancer 
development, long-term survival, and short-term postoperative outcomes. 
This thesis includes four original studies based on a cohort of adult individuals with GERD 
from any of the five Nordic countries from year 1980 onwards. The first study investigates 
the influence of antireflux surgery on laryngeal and pharyngeal cancer. The second study 
evaluates antireflux surgery and risk of lung cancer. The third study examines long-term 
survival after antireflux surgery compared to antireflux medication. The fourth study assesses 






2.1 GASTROESOPHAGEAL REFLUX DISEASE 
The anatomy of the gastroesophageal junction is essential to understanding the 
pathophysiology and treatment options of gastroesophageal reflux disease (GERD). This 
junction connects the 
esophagus to the stomach and 
is located where the proximal 
longitudinal folds of the 
stomach begin. This location 
is normally also where the 
diaphragmatic compression is 
seen as well as where the 
esophageal squamous 
epithelium changes to 
columnar epithelium, also 
called the squamocolumnar 
junction, or Z-line (Figure 
1).(1) In order to maintain an 
antireflux barrier at this site, 
the lower esophageal 
sphincter contains intrinsic 
smooth muscles encircled by 
the crural diaphragm, and 
supported by the stomach’s sling fibers (creating the angle of His) located underneath the 
sphincter.(1) This enables a dynamic exertion of pressure depending on the varying local 
physiologic conditions. The most common mechanisms underlying GERD are prolonged 
transient relaxations of the lower esophageal sphincter and hiatal herniation.(2) Transient 
relaxations of the lower esophageal sphincter, including the crural diaphragm, is a 
physiologic event mediated by a vagal reflex that is independent of swallowing, and allows 
venting of gas from the stomach.(1, 2) In patients with GERD, it is believed that an increased 
compliance of the gastroesophageal junction and an elevated pressure gradient over the 
junction facilitate reflux of stomach content to the esophagus during these relaxations.(3) 
Hiatal herniation anatomically disrupts the antireflux barrier by dislocating the proximal 
stomach partly reaching into the thoracic cavity, which can impair the flap valve mechanism 
created by the stomach’s sling fibers, counteract the clearance of acid from the esophagus, 
and impair the pinchcock-like action exerted on the lower esophageal sphincter by the crural 
diaphragm.(1, 2) 
Since the mid-1990s, the overall prevalence of GERD seems to have increased,(4, 5) and 
GERD is currently a common condition that affects 9% to 28% of adults in the Western 
world and the Middle East, and 3% to 8% of adults in East Asia.(5) Prevalence of GERD 
Figure 1. Anatomy of the gastro-esophageal junction. 
Illustration by Noor Kerdi. 
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increases with higher age in adults, and women seem to have slightly higher prevalence of 
GERD than men.(6) The main risk factors for developing GERD are heredity, obesity, and 
tobacco smoking.(3, 4, 7, 8) In twin studies, a heritability of 31%-43% has been found.(9, 10) 
Obesity is dose-dependently associated with GERD, particularly central obesity, while 
tobacco smoking has a weaker but consistent association with GERD.(3, 6, 7, 11) In a recent 
meta-analysis including 22 studies investigating association between obesity and GERD, and 
30 studies investigating association between tobacco smoking and GERD, the odds ratio 
(OR) of GERD in individuals with obesity compared to no obesity was 1.73 (95% CI, 1.46-
2.06), and in smokers compared to non-smokers the OR was 1.26 (95% CI, 1.04-1.52).(6) 
Lifestyle changes that can reduce symptoms of GERD are mainly weight loss and smoking 
cessation.(12) High alcohol consumption and dietary factors can precipitate reflux episodes 
among patients with GERD, but these exposures have not been found to be associated with 
the development of GERD.(3)  
GERD is defined as a “condition which develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications”, according to the Montreal global evidence-
based consensus.(13) The characteristic symptoms of GERD are heartburn and regurgitation 
of acidic gastric content, i.e. sensation of retrosternal burning and sensation of sourness in the 
pharyngeal or oral cavity.(3, 13) These symptoms vary in frequency and intensity, and are 
often regarded as troublesome and affecting health-related quality of life when mild 
symptoms are experienced two or more days per week, or severe symptoms are experienced 
more than one day per week.(3, 13) In most patients, the severity of GERD will not increase 
with time.(13, 14) Complications of GERD include reflux esophagitis, strictures, dysphagia, 
columnar cell metaplasia (Barrett’s esophagus), and esophageal adenocarcinoma, and the 
presence of these complications (except for esophageal adenocarcinoma) is together with the 
typical symptoms part of the definition of GERD.(3, 13)  
GERD is mainly a clinical diagnosis, mostly based on the cardinal symptoms of heartburn or 
regurgitation, and alleviation of symptoms following a course of proton pump inhibitor (PPI) 
treatment.(13, 15) Upper gastrointestinal endoscopy and pH monitoring have low sensitivity 
in assessing presence of GERD, compared to assessment of the cardinal symptoms of GERD, 
but the latter has a limited specificity.(13, 15) Nonetheless, upper gastrointestinal endoscopy 
should be considered if symptom control is not achieved by a standard course of PPI and if 
malignancy warning symptoms are present, i.e. involuntary weight loss, worsening of 
dysphagia, or signs of gastrointestinal bleeding. If no GERD-related complications are 
present at endoscopy, a 24-hour pH monitoring can be performed to assess abnormal acid 
exposure.(3, 13, 15)  
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2.2 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE 
2.2.1 Antireflux medication 
2.2.1.1 Proton pump inhibitors  
PPIs are the most commonly used and most effective antireflux medication therapy of 
GERD.(16, 17) PPIs act on the gastric parietal cells by irreversibly blocking the H+/K+ 
ATPase, which inhibits acid production in the parietal cells of the stomach.(18) Although 
there are several different PPI drugs, no major difference in reflux symptom control has been 
observed among them.(19) PPI therapy relieves symptoms of heartburn in 37% to 61% of 
patients with GERD who do not have esophagitis. In patients with esophagitis, 56% to 77% 
experience relief of heartburn, and in 72% to 83% of the cases PPI leads to esophagitis 
healing.(16, 17, 20-22) In contrast, PPI use reduces symptoms of regurgitation by 26% to 
64%, which is only 17% more than what is achieved with placebo in patients with 
GERD.(23, 24) An explanation is that PPI does not prevent duodeno-gastric reflux, but only 
reduces its acidic component.(25) Thus, regurgitation will typically remain although with less 
acidic contents. Current guidelines in the treatment of GERD recommend initiation of an 8-
week course of PPI therapy, once a day. This dose can be increased to twice daily if the relief 
of symptoms is insufficient.(26) In patients who relapse in GERD after discontinuing PPI 
therapy, long-term or sometimes life-long use of lowest possible dose of PPI might be 
required.(26, 27) Concerns have arisen regarding side-effects of long-term use of PPI. 
Although the evidence is inconsistent, an increased risk of osteoporosis, bone 
fractures, Clostridium difficile‐associated diarrhea, and gastrointestinal malignancies (mainly 
gastric cancer) following long‐term therapy with PPIs has been suggested.(27) 
2.2.1.2 Histamine-2 receptor antagonists 
Histamine-2 receptor antagonists is a class of anti-acid medication that pre-dates PPIs, and 
reduces gastric acidity by acting as a reversible antagonist of histamine-2 receptors in the 
stomach’s parietal cells.(28) This anti-acid is better than placebo, but less effective in 
relieving symptoms of heartburn and healing esophagitis than PPI.(17, 22) Histamine-2 
receptor antagonists are presently mostly used in conjunction with PPI to enhance symptom 
relief or as a step-down therapy from PPI use.(26) 
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2.3 ANTIREFLUX SURGERY 
The general concept of antireflux surgery (also called fundoplication) is to revive the capacity 
of the antireflux barrier at the site of the gastroesophageal junction by removing any 
herniation, restoring the angle of His and mechanically stabilizing the lower esophageal 
sphincter.(29) In order to accomplish this, the 
distal esophagus is mobilized to an 
appropriate intra-abdominal length (about 3 
cm), and the fundus of the stomach is 
mobilized and wrapped around the distal 
esophagus.(29, 30) In the presence of hiatal 
hernia, an approximation (tightening) of the 
crural diaphragm is also performed.(29, 30) 
Thus, fundoplication mechanically and 
physiologically strives to achieve control of 
acidic and non-acidic duodeno-gastric reflux, 
including enzymes, bile-salts and pancreatic 
juice.(31) Rudolph Nissen first described the 
technical elements of antireflux surgery in 
1956, which included wrapping of the fundus 
by 360 degrees around the esophagus. Several 
modified techniques have been devised by 
other surgeons following studies that has 
shown an increased risk of dysphagia and 
bloating with the Nissen technique, the two 
most common becoming partial posterior 
wrapping of the fundus by 180 to 270 degrees (according to Toupet), or partial anterior 
wrapping of the fundus by 180 degrees (according to Dor) (Figure 2).(29) In the early 1990s, 
laparoscopic antireflux surgery was introduced, which yielded similar reflux symptom 
control compared to open surgery, but reduced postoperative morbidity, length of hospital 
stay and sick leave, and improved cosmetics, thus making it the procedure of choice in 
antireflux surgery treatment.(32, 33) The introduction of laparoscopic antireflux surgery led 
to a surge in antireflux surgery procedures in the 1990s in the Western world, including the 
Nordic countries, which has declined over time following increased use of PPI since the early 
2000s (Figure 3).(34, 35) 
Figure 2. Antireflux surgery techniques 
named after the surgeons that introduced 
them.  




Figure 3. Number of antireflux surgery procedures per 100,000 inhabitants in the five Nordic 
countries from 1980 to 2014 based on data from the Nordic Antireflux Surgery Cohort. 
Several prospective randomized clinical trials and meta-analyses have found similar reflux 
control after total posterior antireflux surgery technique and partial posterior or partial 
anterior antireflux surgery techniques.(36-42) However, two meta-analyses showed that 
anterior techniques might be inferior to posterior techniques concerning reflux control.(43, 
44) Further, three meta-analyses observed that partial antireflux surgery techniques result in 
less postoperative dysphagia and gas-related symptoms compared to a total wrap.(36-38) This 
is supported by a recent randomized clinical trial of 456 participants, which showed a mean 
dysphagia score of 1.3 (SD, 0.9) at 2 years after antireflux surgery with 270 degree posterior 
wrap compared to 1.7 (SD, 1.2) with a 360 degree total wrap.(42)  
Antireflux surgery is considered to be a long-lasting treatment for GERD, and studies have 
shown reflux symptom control in 80-90% of patients at up to 10 years after surgery.(45-47) 
Nonetheless, medical intervention and surgical reintervention with secondary antireflux 
surgery (reoperation) can be required, mainly because of recurrence of GERD. A Swedish 
study of 2655 patients who had undergone primary antireflux surgery showed a reoperation 
rate of 2.9% within a median follow-up of 5.6 years, a study including 13,050 patients from 
the United States observed a reoperation rate of 6.8% within 10 years after primary antireflux 
surgery, and a recent Danish study of 3,717 participants found a reoperation rate of 12.8% 
after 15 years of primary antireflux surgery.(34, 47, 48) 
Severe postoperative complications after antireflux surgery are uncommon. In Western 
populations, short-term postoperative mortality rates are reported to be up to 0.6% after 
primary antireflux surgery and up to 0.8% after secondary antireflux surgery. Rates of other 
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Compared to medical treatment, antireflux surgery seems to have similar or slightly superior 
reflux symptom control in the treatment of GERD. Some studies have also shown a slightly 
superior overall and GERD-associated quality of life, and long-term cost-effectiveness of 
antireflux surgery compared to medication.(26, 54-56) In a study from the United States that 
included 1,892 GERD patients, the cumulative all-cause mortality rate was 47% in 
participants using antireflux medication and 37% in those who had undergone antireflux 
surgery.(57) In contrast, another study from the United States including 239 patients with 
GERD found increased all-cause mortality (relative risk 1.57, 95% confidence interval [CI] 
1.01-2.46) after antireflux surgery, compared to antireflux medication.(58) Because antireflux 
surgery carries a risk of complications, which are rare but still present and sometimes severe, 
medical therapy is recommended as first-line treatment of GERD.(35, 56) Thus, antireflux 
surgery is mainly considered in fit patients with an objectively confirmed diagnosis of GERD 
that respond well to PPI but do not tolerate or wish long-term PPI-treatment.(8) 
2.4 EXTRAESOPHAGEAL MANIFESTATIONS OF GASTROESOPHAGEAL 
REFLUX DISEASE 
Except for the more common symptoms affecting the esophagus, patients with GERD can 
also present with extraesophageal manifestations in the larynx, pharynx, and lungs.(59, 60) 
While GERD seldom is the sole cause of extraesophageal manifestations, a significant 
association has been established with chronic cough, laryngitis, and asthma.(13, 60, 61) 
These manifestations are believed to be due to duodeno-gastric contents reaching above the 
esophagus, leading to laryngo-pharyngeal reflux and airway micro-aspiration, or due to a 
esophageal-bronchial reflex mediated by the vagal nerves.(60, 62) The laryngeal and 
pharyngeal epithelium seems to be particularly vulnerable to inflammatory damage following 
contact with acidic and non-acidic duodeno-gastric contents, including hydrochloric acid, 
pepsin, and bile-salts.(63-67) Suggested associations with other laryngo-pharyngeal and lung 
diseases include pharyngitis, globus pharyngeus, chronic obstructive pulmonary disease, 
idiopathic pulmonary fibrosis, and bronchiolitis obliterans syndrome.(60, 61, 68, 69) 
The evidence of the efficacy of PPI therapy is scant in extraesophageal manifestations of 
GERD. In patients with laryngeal symptoms and chronic cough, less than 25% respond to 
PPI therapy,(70, 71) and in patients with asthma and concomitant heartburn, reflux 
esophagitis or Barrett’s esophagus, PPI therapy can improve peak expiratory flow but with 
limited clinical relevance.(72) Airway symptoms due to GERD may arise regardless of reflux 
acidity,(73) which might explain the limited efficacy of PPI therapy. Thus, clinical guidelines 
recommend objectively ensuring presence of GERD before initiating a PPI course for these 
indications.(26) 
Antireflux surgery is sparsely studied with regards to extraesophageal manifestations of 
GERD. A subset of patients with extraesophageal symptoms, concomitant cardinal symptoms 
of GERD, and previous response to antireflux medication seem to respond better to antireflux 
surgery compared to patients primarily presenting with extraesophageal symptoms.(74, 75) A 
recent systematic review found that, following antireflux surgery, 83% of patients with 
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laryngopharyngeal reflux experienced partial symptom relief and 67% regarded themselves 
cured.(76) There is evidence that in patients with GERD, antireflux surgery might reduce 
chronic cough and asthma symptoms,(77-81) and improve pulmonary function and 
counteract rejection in lung transplantation patients.(82-84) Nonetheless, since the current 
evidence is sparse, and antireflux surgery might provide resolution of extraesophageal 
symptoms only in selected cases, the clinical guidelines generally do not recommend 
antireflux surgery in patients who do not have objectively verified reflux as the cause of 
extraesophageal symptoms, or do not respond to PPI therapy.(26, 85) 
2.5 GASTROESOPHAGEAL REFLUX DISEASE AND ANTIREFLUX 
TREATMENT IN RELATION TO RISK OF SUPRA-ESOPHAGEAL CANCER 
GERD is an established and dose-dependent risk factor of esophageal adenocarcinoma,(86) 
and yet, antireflux surgery does not seem to prevent this tumor.(87) Esophageal 
adenocarcinoma is beyond the scope of the present thesis. GERD appears also to be 
associated with cancer of the larynx and pharynx,(88-98) and an association with lung cancer 
has been suggested.(99-103) A few recently published studies have provided some relevant 
findings in this respect. A population-based case-control study from the United States found 
that the risk was nearly two times higher in developing laryngo-pharyngeal squamous cell 
carcinoma among individuals with GERD who were neither heavy smokers nor heavy 
alcohol drinkers (OR 1.78, 95% CI 1.00-3.16).(92) In a meta-analysis, the risk of developing 
laryngeal cancer was more than two times higher among individuals with GERD or laryngo-
pharyngeal reflux, after controlling for tobacco smoking and alcohol intake (OR 2.07, 95% 
CI 1.26-3.41).(93) These findings were recently supported by a matched case-control study of 
2,094 participants from the United States, showing that after adjusting for tobacco smoking 
and alcohol intake, the risk of laryngeal cancer was increased (OR 1.29, 95% CI 1.04-1.59) in 
participants with GERD.(98) In addition, a very recent meta-analysis showed an increased 
risk for laryngeal cancer (OR 1.95, 95% CI 1.33–2.86), and suggested an increased risk also 
of pharyngeal cancer (OR 1.56, 95% CI 0.86–2.83) in patients with GERD.(104) Finally, a 
recent population-based cohort study observed that individuals with GERD had a more than 
50% increased risk of lung cancer after controlling for tobacco smoking (hazard ratio 1.53, 
95% CI 1.19-1.98).(103) Antireflux surgery has not been studied in relation to the risk of any 
of these supra-esophageal cancers. Only one study has investigated antireflux medication 
(PPI and histamine-2 receptor antagonist) in relation to the risk of developing laryngo-




2.5.1 Cancer of the larynx 
The larynx is an upper airway organ that is mainly composed of a cartilaginous skeleton and 
is located anterior to the hypopharynx, at cervical vertebrae level of C3 to C7.(105) The 
larynx is composed of three subsites, i.e. supraglottis, glottis, and subglottis (Figure 4). Main 
functions of larynx are protection of trachea and the lungs from aspiration and phonation 
through the vocal cords.(105) Laryngeal cancer is one of the most common tumors of the 
respiratory tract, affecting men around five times more often than women.(105) The main 
histological type of laryngeal cancer is squamous cell carcinoma, which approximately 
account for 90% of all laryngeal malignancies.(106) Common warning symptoms of 
laryngeal cancer include 
hoarseness, dysphonia, and 
dysphagia, which should 
prompt clinical examination 
and further investigation with 
flexible nasopharyngoscopy 
for inspection or direct 
laryngoscopy with 
biopsies.(105) At diagnosis, 
about 60% of patients have 
reached an advanced tumor 
stage (III or IV).(105) 
Depending on location, tumor 
stage, and local traditions at 
specialized medical centers, 
treatment might include 
radiotherapy with or without 
surgery, or surgery alone.(105, 
107) The overall 5-year survival is 63%.(105) The main risk factors are tobacco smoking and 
heavy alcohol consumption, and these exposures seem to increase the risk of laryngeal cancer 
by 10 times and 2.5 times, respectively.(108) Except for the possible association between 
GERD and laryngeal cancer, additional potential risk factors are occupational exposures, 
textile dust, and red meat.(109, 110)  
2.5.2 Cancer of the pharynx 
Pharyngeal cancer is predominantly squamous cell carcinoma and is mainly categorized 
based on the subsite from where it arises, i.e. nasopharynx, oropharynx, or hypopharynx 
(Figure 4).(111) Globally, the incidence rate of pharyngeal cancer ranges from 0.8 to 1.4 
cases per 100,000 person-years depending on the subsite,(111) and this tumor occurs two to 
three times more frequently in men than in women.(112-115) Depending on tumor site, 
warning symptoms include dysphagia, odynophagia, dysarthria, epistaxis, unilateral nasal 
obstruction, and neck mass.(116) Diagnosis and treatment of pharyngeal cancer include a 
similar approach to that of laryngeal cancer, but treatment might also include systemic 
Figure 4. Anatomy of larynx and pharynx.  
Illustration by Noor Kerdi. 
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chemotherapy in selected cases.(116) Among the three subsites, the overall 5-year survival 
rate is lowest in hypopharyngeal cancer, ranging from 25 to 40%.(113) The main risk factors 
of pharyngeal cancer are tobacco smoking and heavy alcohol consumption.(117, 118) Except 
for suggested association with GERD, oropharyngeal cancer and nasopharyngeal cancer are 
specifically associated with human papilloma virus and Epstein-Barr virus infection, 
respectively.(112, 115)  
2.5.3 Cancer of the lung 
Lung cancer is estimated to cause 1.6 million deaths per year, making it the most common 
cause of cancer-related death globally.(119) The major histological types of lung cancer are 
adenocarcinoma, squamous cell carcinoma, and small cell lung carcinoma (SCLC). Together 
with other less common histological types of lung cancer, adenocarcinoma and squamous cell 
carcinoma are collectively classified as non-small cell lung carcinoma (NSCLC).(120) 
NSCLC constitute about 85% of all lung cancer, with the rest of cases being SCLC, which is 
a type of neuroendocrine tumor.(120, 121) Although histologically different, NSCLC and 
SCLC can arise in a combined form in lung cancer patients, and there is growing evidence 
that these lung tumors share origins in multipotent stem cells.(121) Unfortunately, most lung 
cancer patients are diagnosed at an advanced tumor stage because of late presentation of 
clinical symptoms and the absence of effective screening programs.(122) NSCLC has an 
overall 5-year survival of 25%, and a 5-year survival of 5.5% in patients with distant 
metastases.(123) SCLC is even more aggressive with rapid growth, early development of 
metastases, and an overall 5-year survival of only 6%.(124) The main risk factor of both 
NSCLC and SCLC is tobacco smoking, accounting for around 80% of lung cancer cases in 
men and 50% of lung cancer cases in women, globally.(125) Other established risk factors 
are genetic susceptibility, air pollution, radon exposure, occupational exposures (mainly 
asbestos), and high doses of radiation.(122, 125) Further, asthma, chronic obstructive 
pulmonary disease, and idiopathic pulmonary fibrosis seem to increase the risk of developing 
lung cancer beyond the effects of their shared risk factor tobacco smoking.(126-128) Over the 
past two decades, progress has been made in improving clinical outcomes of patients with 
NSCLC.(120) However, only modest improvement of detection, therapy, and survival has 
been achieved in patients with SCLC over the past three decades.(129) The most effective 
preventive measure in all major histological types of lung cancer is smoking cessation, which 






The overall aim of the present thesis is to assess antireflux surgery in the prevention of supra-
esophageal cancer risk and mortality. 
The study-specific aims are: 
 To clarify whether antireflux surgery for GERD prevents laryngeal or pharyngeal 
squamous cell carcinoma (Study I) 
 To assess the risk of lung cancer by histological type in patients with GERD 
following antireflux surgery (Study II) 
 To investigate all-cause mortality and disease-specific causes of mortality after 
antireflux surgery for GERD (Study III) 
 To assess the absolute risks and risk factors for poor short-term outcomes after 







Table 1. Overview of methods used in the studies of the thesis. 
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4.2 DATA SOURCES 
4.2.1 The patient registries in the Nordic countries 
The patient registries in the Nordic countries include data on patient characteristics, dates of 
admission and discharge, and diagnosis and surgical procedure codes, all from in-hospital and 
specialized out-patient care. The diagnosis codes registered in each national patient registry 
follow the International Statistical Classification of Diseases and Related Health Problems 
(ICD), with some country-specific variations in the coding. In Finland and Sweden, the ICD-
versions used in the national patient registries have been updated rather simultaneously 
following each update of the ICD. In Denmark, the national patient registry migrated directly 
from ICD version 8 to version 10, while in Iceland and Norway, ICD version 10 has been 
used since the inception of their respective national patient registry.(130) The Nordic 
Medico-Statistical Committee (NOMESCO) Classification of Surgical Procedures was 
introduced in 1996, and was adopted by all Nordic countries closely thereafter, which 
provided a more standardized approach to surgical procedure coding and enabled distinction 
between open and laparoscopic procedures.(131) Nationwide coverage of in-hospital care in 
the patient registries was reached in the 1970s (Finland), 1978 (Denmark), 1987 (Sweden), 
1997 (Norway), and 1999 (Iceland). While the patient registry of Iceland does not include 
specialized out-patient care, coverage of specialized out-patient care in the other Nordic 
countries has been nationwide from 1994 (Finland), 1995 (Denmark), 2001 (Sweden), and 
2006 (Norway). The completeness of the national patient registries is high because the 
healthcare in the Nordic countries is mainly public, the reporting to the national patient 
registries is mandatory by law, and the reimbursement to the healthcare providers depend on 
this reporting.(132, 133) The validity of the national patient registries has been mainly 
investigated in Denmark, Finland, and Sweden, and studies have shown a positive predictive 
value of 15-100%, 75-99%, and 85-95%, respectively.(130, 134, 135) 
4.2.2 The cancer registries in the Nordic countries 
The national cancer registries in the Nordic countries include data on date of cancer 
diagnosis, patient demographics at cancer diagnosis, histological type and location of the 
tumor, and source of cancer confirmation. All Nordic cancer registries have very high 
national completeness from their initiation in 1943 (Denmark), 1953 (Finland), 1953 
(Norway), 1955 (Iceland) and 1958 (Sweden).(136) The reporting to the registries has been 
mandatory from or shortly after their inception, except for in Denmark, where reporting 
became mandatory in 1987.(133) Microscopic verification of the registered tumors ranges 
between 93-98% between the Nordic countries.  Numerous validation studies have shown 
high completeness (≥98%) and accuracy (≥94%) of the cancer registration.(136) 
4.2.3 The cause of death registries in the Nordic countries 
The national cause of death registries contain information on date of death, and primary and 
other underlying causes of death, mainly collected from death certificates. These national 
registries have been nationwide with mandatory registration since their initiation in 1951 
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(Norway), 1952 (Sweden), 1952 (Iceland), 1969 (Finland) and 1970 (Denmark).(133) The 
completeness of date of death and cause of death in the Swedish cause of death registry has 
been shown to be 100% and 96% complete, respectively.(137) A Swedish study has shown 
77% agreement between cause of death according to the medical records, compared to cause 
of death in the Swedish cause of death registry.(138) 
4.2.4 The registries of the total population in the Nordic countries 
The national registries of the total population include data such as birth and country of birth, 
sex, death, marital status, migration and citizenship. These registries have been nationwide 
since 1953 (Iceland), 1964 (Norway), 1968 (Denmark), 1968 (Sweden), and 1971 (Finland), 
and are considered entirely representative of the total national populations with virtually no 
loss to follow-up. The reporting of births and deaths within 30 days to these registries is 
estimated to be 100%.(139, 140) 
4.2.5 The prescribed drug registry in Sweden 
The Swedish prescribed drug registry include data on all prescribed and dispensed 
medications in Sweden, and has been nationwide since initiation in July 1, 2005. The 
coverage is virtually 100% and the reporting is mandatory according to Swedish law.(141)  
4.2.6 Nordic antireflux surgery cohort 
This thesis utilizes the Nordic antireflux surgery cohort (NordASCo) as the source cohort. 
This cohort has been presented in detail in a separate cohort profile.(133) In short, NordASCo 
is a population-based cohort that includes merged data from the national patient registries, 
cancer registries and cause of death registries in the five Nordic countries, i.e. Denmark, 
Finland, Iceland, Norway, and Sweden. The inclusion criteria in NordASCo is a documented 
GERD diagnosis or antireflux surgery procedure recorded in a national patient registry in any 
Nordic country from year 1980 to 2014 (Supplementary Table 1). There are differences in the 
start and end years between the countries, which is due to availability of data. The start and 
end years were 1980-2014 (Denmark), 1980-2013 (Sweden), 1986-2013 (Finland), 2000-
2013 (Iceland), and 2008-2013 (Norway). More recently, NordASCo was updated to also 
include data from 1980-2018 in Finland and 1980-2018 in Sweden. The similar structure of 
the national health data registries in the Nordic countries, combined with the well-established 
system of a unique personal identity number assigned to each resident in all Nordic countries, 




4.3 STUDY DESIGN 
4.3.1 Study I 
4.3.1.1 Design 
Population-based cohort study in the five Nordic countries that investigated the risk of 
laryngeal and pharyngeal squamous cell carcinoma after antireflux surgery or no such surgery 
in patients with GERD, from 1980 through 2014. 
4.3.1.2 Cohort 
This study was based on NordASCo and included a main cohort and a sub-cohort. The main 
cohort included participants with a documented diagnosis of GERD in any of the national 
patient registries in the Nordic countries and were aged ≥18 and ≤95 years at the time of first 
GERD diagnosis. The sub-cohort was restricted to participants with severe GERD diagnosis 
that require objective confirmation by endoscopy and histology, i.e. reflux esophagitis or 
Barrett’s esophagus. Excluded were patients with recorded laryngeal or pharyngeal 
carcinoma before diagnosis of GERD. Moreover, participants from Norway were excluded 
from the sub-cohort because the four-character sub-categories of diagnosis codes that are 
required for identification of severe GERD were not available in the Norwegian patient 
registry. The outcomes laryngeal and pharyngeal squamous cell carcinoma were identified 
through the national cancer registries of each country.  
4.3.1.3 Follow-up 
To counteract detection bias of earlier detection of laryngeal or pharyngeal squamous cell 
carcinoma due to the diagnosis of GERD or the antireflux surgery procedure, the first year of 
follow-up was excluded. A participant contributed to person-years at risk to the antireflux 
surgery group with GERD from one year after the date of antireflux surgery procedure, until 
the date of laryngeal or pharyngeal squamous cell carcinoma, death, or end of study period, 
whichever occurred first. A participant contributed to person-years at risk to the non-operated 
group with GERD from one year after the date of first GERD diagnosis, until the date of 
laryngeal or pharyngeal squamous cell carcinoma, antireflux surgery, death, or end of study 
period, whichever occurred first. 
4.3.1.4 Statistical analysis 
Measures of effect were calculated by using two statistical methods. In the first approach, the 
incidence of laryngeal and pharyngeal squamous cell carcinoma in the antireflux surgery 
group and the non-operated group was compared to their corresponding general Nordic 
background population. Standardized incidence ratios (SIR) and 95% CIs were calculated by 
dividing the observed number of laryngeal or pharyngeal squamous cell carcinoma in the 
cohort groups by the expected number among individuals of the same country, sex (men or 
women), age (5-year categories), and calendar period (5-year categories). The SIRs were 
calculated for the overall follow-up period, and stratified into the follow-up categories >1-5, 
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>5-10, >10-15, and >15 years. In the second approach, the incidence of laryngeal and 
pharyngeal squamous cell carcinoma in the antireflux surgery group was compared directly to 
the non-operated group by using multivariable Cox regression to calculate hazard ratios (HR) 
and 95% CIs, adjusted for sex (male or female), age (continuous), calendar period (1980-
1989, 1990-1999, or 2000-2014), country (Denmark, Finland, Iceland, Norway, or Sweden), 
chronic obstructive pulmonary disease (yes or no), obesity diagnosis or diabetes mellitus type 
2 (yes or no), and alcohol-related diagnoses (yes or no). The HRs were calculated for the 
entire follow-up period and for the same follow-up categories as above. 
4.3.2 Study II 
4.3.2.1 Design 
Population-based cohort study in the five Nordic countries that investigated the separate risk 
of small cell carcinoma, squamous cell carcinoma, and adenocarcinoma of the lung following 
antireflux surgery or no such surgery for GERD in 1980 to 2014. 
4.3.2.2 Cohort 
Similar to Study I, this study cohort used NordASCo and had a main cohort of participants 
with any GERD and a sub-cohort of participants with severe GERD, i.e. reflux esophagitis or 
Barrett’s esophagus. Participants were aged ≥18 and ≤95 years at the time of first GERD 
diagnosis. Participants with any recorded lung cancer before diagnosis of GERD were 
excluded, and Norwegian GERD patients were excluded from the sub-cohort due to 
unavailability of four-character sub-categories in the Norwegian patient registry, which are 
required for identification of esophagitis and Barrett’s esophagus. The outcomes small cell 
carcinoma, squamous cell carcinoma, and adenocarcinoma of the lung were identified 
through the national cancer registries of each country. Individuals who were identified with 
histological subtypes that were ill-defined, or that potentially represented poor or 
undifferentiated forms of lung cancer, were excluded to avoid misclassification. 
4.3.2.3 Follow-up 
The follow-up was the same as in Study I. Accumulation of person-years at risk to the 
antireflux surgery group started from one year after the date of antireflux surgery, until the 
date of any lung cancer, death, or end of study period. Accumulation of person-years at risk 
to the non-operated group started from one year after the date of first GERD diagnosis, until 
the date of any lung cancer, antireflux surgery, death, or end of study period. 
4.3.2.4 Statistical analysis 
The two statistical approaches to calculating measures of effect in Study I were similarly 
applied in Study II. The incidence of small cell carcinoma, squamous cell carcinoma, and 
adenocarcinoma of the lung in the antireflux surgery group and the non-operated group was 
compared to the background population by calculating SIRs and 95% CIs. This was 
performed by dividing the observed cases of small cell carcinoma, squamous cell carcinoma, 
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and adenocarcinoma of the lung in the antireflux surgery group and the non-operated group 
by the expected cases in individuals of the corresponding country, sex (men or women), age 
(5-year categories), and calendar period (5-year categories). SIRs were computed for the 
entire follow-up period, and categorized into >1-5, >5-10, >10-15, and >15 years of follow-
up. Secondly, calculation of incidence rate ratio of small cell carcinoma, squamous cell 
carcinoma, and adenocarcinoma of the lung was performed, comparing tumor incidence in 
the antireflux surgery group to that of the non-operated group. For this purpose, a 
multivariable Cox regression was applied, which provided HRs and 95% CIs, adjusted for 
sex (male or female), age (continuous), calendar period (1980-1989, 1990-1999, or 2000-
2014), country (Denmark, Finland, Iceland, Norway, or Sweden), chronic obstructive 
pulmonary disease (yes or no), and obesity diagnosis or diabetes mellitus type 2 (yes or no). 
The HRs were computed for overall follow-up, and categorized as in the SIR-analyses.  
4.3.3 Study III 
4.3.3.1 Design 
Multinational population-based cohort study that investigated mortality, comparing patients 
with reflux esophagitis or Barrett’s esophagus who have undergone antireflux surgery with 
those using antireflux medication from 1980 to 2014. 
4.3.3.2 Cohort 
This cohort included all individuals aged ≥18 and ≤70 years with a documented diagnosis of 
objectively determined reflux esophagitis or Barrett’s esophagus in NordASCo, except for 
Norway where data on reflux esophagitis or Barrett’s esophagus were not available. 
Individuals with documented cancer in the esophagus, larynx, pharynx or lung before 
diagnosis of reflux esophagitis or Barrett’s esophagus were excluded. The outcomes were all-
cause mortality (main), and disease-specific mortality (secondary), i.e. mortality from 
cardiovascular disease, respiratory disease, esophageal cancer, laryngeal or pharyngeal 
cancer, or lung cancer. These were identified in the cause of death registries. 
4.3.3.3 Exposure 
Individuals with reflux esophagitis or Barrett’s esophagus who had documented open or 
laparoscopic antireflux surgery in the national patient registries were compared with those 
using antireflux medication (mainly proton pump inhibitors, or occasionally histamine-2 
receptor antagonists). Direct data on antireflux medication were available from the Swedish 
prescribed drug registry, which was utilized to confirm the use of antireflux medication in a 
validation sample of 7,339 Swedish non-operated participants with reflux esophagitis or 
Barrett’s esophagus. Among these, 7,143 (97.3%) had dispensed prescriptions of antireflux 
medication, of whom 6,530 (91.4%) obtained their first prescription within 3 months before 




Follow-up of study participants began from the first diagnosis date of reflux esophagitis or 
Barrett’s esophagus, until date of antireflux surgery, death or end of study. Participants who 
underwent antireflux surgery were censored from the non-operated group at the date of 
antireflux surgery, and were from that date included in the follow-up of the antireflux surgery 
group instead. 
4.3.3.5 Statistical analysis 
Multivariable Cox regression was used to calculate HRs and 95% CIs, comparing mortality in 
the antireflux surgery group to that of the antireflux medication group. Five potential 
confounders were adjusted for in the model: sex (female or male), age (continuous variable), 
calendar period (1980-1989, 1990-1999, or 2000-2014), country of residence (Denmark, 
Finland, Iceland, or Sweden), and comorbidity (Charlson Comorbidity Index score 0, 1, or 
>2). HRs were calculated for the entire follow-up period, and for four follow-up categories: 
0-5, >5-10, >10-15, and >15 years. Stratification by sex, age, comorbidity, and surgical 
approach (open or laparoscopic fundoplication) was performed in the analyses of all-cause 
mortality (main outcome). Analyses including surgical approach were restricted to a sub-
cohort of participants the years 1996 to 2014 due to lack of data before year 1996. 
4.3.4 Study IV 
4.3.4.1 Design 
Multinational population-based cohort study that investigated all-cause 90-day mortality, 90-
day reoperation, and prolonged hospital stay, following primary laparoscopic or secondary 
antireflux surgery from year 2000 to 2018. 
4.3.4.2 Cohort 
This study was based on an updated version of NordASCo, and included all individuals aged 
≥18 and ≤80 years with a recorded elective primary laparoscopic antireflux surgery in any of 
the national patient registries in the five Nordic countries. The update of NordASCo entailed 
collection of data from the national patient registries and cause of death registries in Finland 
and Sweden, up to year 2018. A sub-cohort of study participants included those who 
underwent elective secondary antireflux surgery after having undergone a primary 
laparoscopic antireflux procedure. Excluded were individuals who underwent antireflux 
surgery in an emergency setting or those who had surgery following incarcerated hernia. The 
main outcome was all-cause 90-day postoperative mortality and secondary outcomes were 
reoperation within 90 days of surgery due to complications, and prolonged hospital stay (≥2 
days longer than the median length of hospital stay) after primary laparoscopic or secondary 
antireflux surgery. Mortality data came from the cause of death registries and length of 
hospital stay was defined as number of days from date of admission to date of discharge in 
the national patient registries. 
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4.3.4.3 Statistical analyses 
Frequencies of absolute rates of mortality and reoperation were calculated. Multivariable 
logistic regression provided ORs with 95% CIs of the outcomes, adjusted for age, sex, 
comorbidity, hospital volume, and calendar period. A cubic spline model was used to assess 
the influence of the continuous covariates age, year of surgery, and annual hospital volume 
on the odds of prolonged hospital stay, adjusted for the other exposures. The results of these 
were presented in probability graphs with the following reference values: age 43-55 years, 
male, Charlson Comorbidity Index 0, calendar year 2000-2003, and Finland.   
4.4 ETHICAL CONSIDERATIONS 
In all Nordic countries, informed consent is not required for registry-based research. While 
ethical permissions are not required in Denmark and Finland for this type of registry-based 
research, permissions from relevant ethical committees in Iceland (VSN-14-083), Norway 
(2014/1498-3) and Sweden have been acquired (2014/234-31, 2015/240-32 and 2019-04509). 
The data collected from the Nordic patient registries, cancer registries, and cause of death 
registries were completely de-identified, without possibility of any identifiable personal 
information, and the merging of the data from the different registries was anonymously 
performed. Storage of datasets was electronic, on safe servers at Statistics Denmark or 
Karolinska Institute. Datasets were password protected and access to them was strictly 
limited to the few researchers involved in the data management and analysis process. 





5.1 STUDY I 
In Study I, 814,230 patients with GERD were included in the cohort, of which 47,016 (5.8%) 
underwent antireflux surgery. Among the 269,656 patients with severe GERD, 34,766 
(12.9%) underwent antireflux surgery.  
 
Table 2. Characteristics of participants included in Study I. 







Total    
Patients 47,016 (100) 780,546 (100) 
Person-years of follow-up 556,234 5,020,529 
Sex    
Male 26,478 (56.3) 378,757 (48.5) 
Female 20,538 (43.7) 401,789 (51.5) 
Age at inclusion   
<50 years 22,095 (47.0) 256,475 (32.9) 
50-<65 years 18,226 (38.8) 237,604 (30.4) 
>65 years 6,695 (14.2) 286,467 (36.7) 
Laryngeal or pharyngeal squamous cell 
carcinoma 
39 (0.08)[100] 699 (0.09)[100] 
Laryngeal squamous cell carcinoma 20 [51.3] 311 [44.5] 
Pharyngeal squamous cell carcinoma 19 [48.7] 388 [55.5] 







Total    
Patients 34,766 (100) 242,619 (100) 
Person-years of follow-up 425,331 1,996,651 
Sex    
Male 20,065 (57.7) 133,827 (55.2) 
Female 14,701 (42.3) 108,792 (44.8) 
Age at inclusion   
<50 years 16,737 (48.1) 76,813 (31.7) 
50-<65 years 13,768 (39.6) 76,918 (31.7) 
>65 years 4,261 (12.3) 88,888 (36.6) 
Laryngeal or pharyngeal squamous cell 
carcinoma 
28 (0.08)[100] 321 (0.13)[100] 
Laryngeal squamous cell carcinoma 12 [42.9] 148 [46.1] 
Pharyngeal squamous cell carcinoma 16 [57.1] 173 [53.9] 
   
 
26 
Table 2 shows some characteristics of the study participants. Among participants with 
GERD, 39 (0.08%) were identified with laryngeal or pharyngeal squamous cell carcinoma in 
the antireflux surgery group during follow-up, and 699 (0.09%) in the non-operated group. 
Among those with severe GERD (sub-cohort), 28 (0.08%) and 321 (0.13%) were identified 
with these tumors in the antireflux surgery group and the non-operated group, respectively. 
Comparing operated patients with GERD with the corresponding background population, a 
decrease in the overall SIRs was seen for laryngeal or pharyngeal squamous cell carcinoma 
(SIR 0.62, 95% CI 0.44-0.85), and after more than 10 years of follow-up, the point estimate 
was further reduced (SIR 0.48, 95% CI 0.26-0.80) (Table 3). When analyzed separately, the 
overall SIR was decreased for laryngeal squamous cell carcinoma (SIR 0.65, 95% CI 0.40-
1.00) and pharyngeal squamous cell carcinoma (SIR 0.60, 95% CI 0.36-0.93). The SIR 
reduced further after more than 10 years of follow-up for laryngeal squamous cell carcinoma 
(SIR 0.28, 95% CI 0.08-0.72), but no such decrease over time was observed for pharyngeal 
squamous cell carcinoma (Table 3). Non-operated patients with GERD had similar incidence 
of laryngeal or pharyngeal squamous cell carcinoma (analyzed combined and separately) to 
that of the corresponding background population (Table 3). The analyses of patients of the 
sub-cohort with severe GERD yielded similar results to that of the main cohort. 
 
Comparing operated patients with non-operated patients with GERD, the overall adjusted HR 
was decreased for laryngeal or pharyngeal squamous cell carcinoma (HR 0.55, 95% CI 0.38-
0.80), and a slight further reduction of the point estimate was observed after more than 10 
years of follow-up (HR 0.47, 95% CI 0.26-0.85) (Table 4). In the separate analyses of the 
Table 3. SIRs and 95% CIs of laryngeal and pharyngeal squamous cell carcinoma (SCC) 






















>1-34 39 0.62 (0.44-0.85) 20 0.65 (0.40-1.00) 19 0.60 (0.36-0.93) 
       
>1-5 8 0.54 (0.23-1.07) 5 0.67 (0.22-1.57) 3 0.41 (0.08-1.20) 
>5-10 17 0.91 (0.53-1.45) 11 1.20 (0.60-2.14) 6 0.63 (0.23-1.37) 
>10 14 0.48 (0.26-0.80) 4 0.28 (0.08-0.72) 10 0.67 (0.32-1.23) 
 
No antireflux surgery 
>1-34 699 1.00 (0.93-1.08) 311 0.94 (0.84-1.05) 388 1.06 (0.96-1.17) 
       
>1-5 305 1.05 (0.94-1.17) 133 0.95 (0.79-1.12) 172 1.15 (0.98-1.33) 
>5-10 212 0.99 (0.87-1.14) 99 0.99 (0.80-1.20) 113 1.00 (0.83-1.20) 
>10 182 0.95 (0.81-1.09) 79 0.88 (0.70-1.10) 103 1.00 (0.82-1.21) 
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tumor types, the overall adjusted HR was decreased for laryngeal (HR 0.53, 95% CI 0.31-
0.90) and pharyngeal (HR 0.58, 95% CI 0.35-0.96) squamous cell carcinoma. The HRs 
further decreased after more than 10 years of follow-up for laryngeal squamous cell 
carcinoma (HR 0.23, 95% CI 0.08-0.69), but not for pharyngeal squamous cell carcinoma 
(Table 4). The analyses of patients of the sub-cohort with severe GERD yielded mainly 
similar results to that of the main cohort. 
5.2 STUDY II 
Study II included 812,617 participants with GERD, of which 46,996 (5.8%) underwent 
antireflux surgery. During follow-up, lung cancer was identified in 3,650 (0.5%) and 273 
(0.6%) patients in the non-operated group and in the antireflux surgery group, respectively. 
Among the 269,318 of participants with severe GERD (sub-cohort), 34,752 (12.9%) 
underwent antireflux surgery. Lung cancer was identified in 1,491 (0.6%) patients in the non-
operated group and in 191 (0.5%) patients in the antireflux surgery group. 
Table 4. Risk of laryngeal and pharyngeal squamous cell carcinoma (SCC) in GERD 
patients who had antireflux surgery or not, presented as HRs with 95% CIs. 
  
No antireflux surgery 
 
Antireflux surgery 











Adjusted ⱡ HR 
(95% CI) 
      
Laryngeal or pharyngeal SCC 
>1-34 699 1.00 (Reference) 39 0.48 (0.34-0.66) 0.55 (0.38-0.80) 
      
>1-5 305 1.00 (Reference) 8 0.36 (0.18-0.73) 0.36 (0.16-0.82) 
>5-10 212 1.00 (Reference) 17 0.68 (0.41-1.11) 0.92 (0.53-1.60) 
>10 182 1.00 (Reference) 14 0.40 (0.23-0.69) 0.47 (0.26-0.85) 
      
Laryngeal SCC 
>1-34 311 1.00 (Reference) 20 0.55 (0.35-0.87) 0.53 (0.31-0.90) 
      
>1-5 133 1.00 (Reference) 5 0.52 (0.21-1.27) 0.43 (0.15-1.25) 
>5-10 99 1.00 (Reference) 11 0.94 (0.51-1.76) 1.17 (0.57-2.41) 
>10 79 1.00 (Reference) 4 0.26 (0.10-0.71) 0.23 (0.08-0.69) 
      
Pharyngeal SCC 
>1-34 388 1.00 (Reference) 19 0.42 (0.26-0.66) 0.58 (0.35-0.96) 
      
>1-5 172 1.00 (Reference) 3 0.24 (0.08-0.75) 0.30 (0.08-1.09) 
>5-10 113 1.00 (Reference) 6 0.45 (0.20-1.02) 0.69 (0.29-1.64) 
>10 103 1.00 (Reference) 10 0.52 (0.27-0.99) 0.72 (0.36-1.46) 
      
ⱡ Adjusted for sex, age (continuous), calendar period, country, chronic obstructive pulmonary 




Comparing operated patients with GERD to the corresponding background population, a 
decrease in the overall SIRs was observed for small cell carcinoma (SIR 0.57, 95% CI 0.41-
0.77) and squamous cell carcinoma (SIR 0.75, 95% CI 0.60-0.92), but not for 
adenocarcinoma (SIR 0.90, 95% CI 0.76-1.06) of the lung (Table 5). The SIRs did not 
decrease with longer follow-up. Patients of the sub-cohort with severe GERD had similar 
results to that of the main cohort.  
Comparing non-operated patients with GERD to the corresponding background population, a 
decrease in the overall SIRs was seen for all three histological types of lung cancer, and the 
SIRs did not change much over time (Table 5). Similar results were observed for severe 
GERD. 
 
Compared to non-operated patients with GERD, those who underwent antireflux surgery had 
decreased adjusted HRs for small cell carcinoma (HR 0.63, 95% CI 0.44-0.90), decreased 
point estimate for squamous cell carcinoma (HR 0.80, 95% CI 0.62-1.03), and no decreased 
risk of adenocarcinoma (HR 1.03, 95% CI 0.84-1.26). No further decrease of the HRs over 
longer follow-up time was observed for any of the histological types (Table 6).  
 
Table 5. SIRs and 95% CIs of lung cancer by histological type in GERD patients 
compared to the background population. 
 Small cell carcinoma 
 

















>1-34 43 0.57 (0.41-0.77) 88 0.75 (0.60-0.92) 142 0.90 (0.76-1.06) 
       
>1-5 14 0.75 (0.41-1.26) 16 0.59 (0.34-0.95) 24 0.74 (0.47-1.09) 
>5-10 7 0.31 (0.12-0.64) 25 0.73 (0.47-1.08) 42 0.94 (0.68-1.27) 
>10-15 11 0.62 (0.31-1.11) 19 0.67 (0.40-1.05) 40 1.00 (0.72-1.37) 
>15 11 0.68 (0.34-1.22) 28 1.00 (0.66-1.44) 36 0.89 (0.62-1.23) 
 
No antireflux surgery 
>1-34 724 0.83 (0.77-0.89) 1152 0.87 (0.82-0.92) 1774 0.83 (0.80-0.87) 
       
>1-5 332 0.86 (0.77-0.96) 550 0.95 (0.87-1.03) 786 0.88 (0.82-0.94) 
>5-10 200 0.77 (0.67-0.89) 322 0.81 (0.73-0.91) 562 0.87 (0.80-0.95) 
>10-15 114 0.82 (0.67-0.98) 160 0.76 (0.64-0.88) 274 0.76 (0.68-0.86) 




5.3 STUDY III 
In Study III, 240,226 participants were identified with reflux esophagitis or Barrett’s 
esophagus. Table 7 shows some characteristics of the study participants. Among all 
participants, 33,904 (14.1%) had undergone antireflux surgery. In the antireflux medication 
group, 39,390 (19.1%) died of any cause, and in the antireflux surgery group, 4,496 (13.3%) 





Table 6. Risk of lung cancer by histological type in GERD patients who had antireflux 
surgery or not, presented as HRs with 95% CIs. 
  
No antireflux surgery 
 
Antireflux surgery 











Adjusted ⱡ HR 
(95% CI) 
      
Small cell carcinoma 
>1-34 724 1.00 (Reference) 43 0.51 (0.37-0.69) 0.63 (0.44-0.90) 
      
>1-5 332 1.00 (Reference) 14 0.58 (0.34-0.99) 0.81 (0.44-1.49) 
>5-10 200 1.00 (Reference) 7 0.30 (0.14-0.64) 0.37 (0.16-0.89) 
>10-15 114 1.00 (Reference) 11 0.57 (0.31-1.06) 0.66 (0.32-1.37) 
>15 78 1.00 (Reference) 11 0.62 (0.33-1.17) 0.71 (0.37-1.38) 
      
Squamous cell carcinoma 
>1-34 1152 1.00 (Reference) 88 0.66 (0.53-0.82) 0.80 (0.62-1.03) 
      
>1-5 550 1.00 (Reference) 16 0.40 (0.24-0.66) 0.58 (0.33-1.03) 
>5-10 322 1.00 (Reference) 25 0.67 (0.44-1.00) 0.74 (0.45-1.21) 
>10-15 160 1.00 (Reference) 19 0.71 (0.44-1.14) 0.86 (0.50-1.49) 
>15 120 1.00 (Reference) 28 1.02 (0.68-1.54) 1.13 (0.72-1.77) 
      
Adenocarcinoma 
>1-34 1774 1.00 (Reference) 142 0.70 (0.58-0.82) 1.03 (0.84-1.26) 
      
>1-5 786 1.00 (Reference) 24 0.42 (0.28-0.62) 0.83 (0.52-1.32) 
>5-10 562 1.00 (Reference) 42 0.64 (0.47-0.87) 1.07 (0.74-1.54) 
>10-15 274 1.00 (Reference) 40 0.88 (0.63-1.22) 1.09 (0.73-1.62) 
>15 152 1.00 (Reference) 36 1.05 (0.73-1.51) 1.12 (0.75-1.67) 
      
ⱡ Adjusted for sex, age (continuous), calendar period, country, obesity diagnosis, diabetes 




The comparison of participants in the antireflux surgery group with those in the antireflux 
medication group is shown in Table 8. Comparing antireflux surgery with medication, the 
adjusted risk of all-cause mortality was decreased (HR 0.61, 95% CI 0.58-0.63), and 
remained decreased over time. The adjusted risk of all-cause mortality risk was similarly 
decreased between sexes and age groups, but more decreased in participants with 
comorbidity (HR 0.47 [95% CI 0.37-0.58] for Charlson comorbidity score ≥2) compared to 
participants without comorbidity (HR 0.62 [95% CI 0.59-0.64] for Charlson comorbidity 
score 0).  
Table 7. Characteristics of participants included in Study III. 
 




   
Patients 33,904 (100) 206,322 (100)* 
   
Person-years 445,594 (100) 1,851,087 (100) 
   
Sex    
Men 19,757 (58.3) 119,255 (57.8) 
Women 14,147 (41.7) 87,067 (42.2) 
Age at inclusion   
<50 years 16,927 (49.9) 86,221 (41.8) 
50-<65 years 13,959 (41.2) 86,517 (41.9) 
>65 years 3,018 (8.9) 33,584 (16.3) 
Charlson Comorbidity Index 
score 
  
0 31,172 (91.9) 173,499 (84.1) 
1 2,466 (7.3) 25,403 (12.3) 
>2 266 (0.8) 7,420 (3.6) 
Surgical approach (1996 – 2014) ⱡ   
Any approach 23,656 (69.8) [100] Not applicable 
Laparoscopic approach 21,231 [89.7) Not applicable 
Open approach 2,332 [9.9] Not applicable 
Converted to open 93 [0.4] Not applicable 
Causes of mortality    
All causes 4,496 (13.3) 39,390 (19.1) 
Cardiovascular diseases 2,159 (6.4) 19,102 (9.3) 
Respiratory diseases 1,154 (3.4) 10,229 (5.0) 
Esophageal cancer 158 (0.5) 964 (0.5) 
Laryngeal or pharyngeal cancer 13 (0.0) 270 (0.1) 
Lung cancer 257 (0.8) 2,253 (1.1) 
   
* Among the non-operated patients, 20,272 were included in the operated group after 
they were censored from the non-operated group at the date of admission to antireflux 
surgery. 
ⱡ Restricted to the study period 1996-2014, from which data on antireflux surgery 
approach were available. 
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Comparing antireflux surgery with antireflux medication with regards to disease-specific 
mortality, the adjusted overall HRs were decreased for mortality from cardiovascular disease 
(HR 0.58, 95% CI 0.55-0.61), respiratory disease (HR 0.62, 95% CI 0.57-0.66), laryngeal or 
pharyngeal cancer (HR 0.35, 95% CI 0.19-0.65), and lung cancer (HR 0.67, 95% CI 0.58-
0.80), but not from esophageal cancer (HR 1.05, 95% CI 0.87-1.28). The reduced HRs stayed 
decreased over time, and the HR was particularly decreased for laryngeal or pharyngeal 
cancer after more than 15 years of follow-up (HR 0.18, 95% CI 0.04-0.81). 
5.4 STUDY IV 
In Study IV, 26,193 patients had undergone elective primary laparoscopic antireflux surgery 
for GERD, and 1,618 patients also underwent elective secondary antireflux surgery.  
The absolute rate of 90-day mortality was 0.13% (n=35) after primary laparoscopic antireflux 
surgery and 0.19% (n=3) after secondary antireflux surgery. Cardiovascular disease and 
suicide or intoxication were the most common causes of death. The ORs of 90-day all-cause 
mortality and 90-day reoperation following primary laparoscopic antireflux surgery are 
presented in Table 9. The adjusted ORs of 90-day mortality increased in participants with 
higher age (highest vs lowest tertile: OR 2.66, 95% CI 1.03-6.85) and in participants with 
comorbidity (Charlson Comorbidity Index ≥2 vs 0: OR 6.25, 95% CI 2.42-16.14). The risk 
Table 8. All-cause mortality in patients with reflux esophagitis or Barrett’s esophagus 
comparing antireflux surgery with medication, presented as HRs with 95% CIs. 
  
No antireflux surgery 
 
Antireflux surgery 











Adjusted ⱡ HR 
(95% CI) 
      
Follow-up (years) 
0-34 39,390 1.00 (Reference) 4,496 0.46 (0.45-0.48) 0.61 (0.58-0.63) 
      
>1-5 15,697 1.00 (Reference) 784 0.26 (0.24-0.28) 0.41 (0.38-0.45) 
>5-10 9,121 1.00 (Reference) 991 0.43 (0.40-0.46) 0.54 (0.50-0.58) 
>10-15 6,871 1.00 (Reference) 1,116 0.53 (0.50-0.57) 0.63 (0.59-0.68) 
>15 7,701 1.00 (Reference) 1,605 0.71 (0.67-0.75) 0.76 (0.72-0.81) 
Sex 
Men 25,936 1.00 (Reference) 2,901 0.44 (0.42-0.45) 0.59 (0.56-0.61) 
Women 13,454 1.00 (Reference) 1,595 0.51 (0.48-0.53) 0.64 (0.61-0.68) 
Age at inclusion (years) 
<50  7,771 1.00 (reference) 1,125 0.53 (0.50-0.57) 0.62 (0.57-0.66) 
50-<65 18,511 1.00 (reference) 2,255 0.48 (0.45-0.50) 0.59 (0.56-0.62) 
>65 13,108 1.00 (reference) 1,116 0.56 (0.53-0.60)  0.65 (0.61-0.70) 
Charlson Comorbidity Index score 
0 25,430 1.00 (reference) 3,905 0.56 (0.54-0.58) 0.62 (0.59-0.64) 
1 9,765 1.00 (reference) 505 0.38 (0.35-0.42) 0.48 (0.44-0.53) 
>2 4,195 1.00 (reference) 86 0.37 (0.30-0.46) 0.47 (0.37-0.58) 
      
ⱡ Adjusted for sex, age, calendar period, country of residence, and Charlson Comorbidity Index 
score (excluding the variable analyzed). 
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was not influenced by sex. Although not statistically significant, the point estimates of higher 
hospital volume were decreased (highest vs lowest tertile: OR 0.58, 95% CI 0.22-1.57). 
The 90-day reoperation rate was 3.0% (n=750) after primary laparoscopic antireflux surgery 
and 6.2% (n=94) after secondary antireflux surgery. Comparing greater Charlson comorbidity 
index scores with score of 0, the OR of 90-day reoperation was increased (Charlson 
Comorbidity Index ≥2 vs 0: OR 1.47, 95% CI 0.97-2.23; and Charlson Comorbidity Index 1 
vs 0: OR 1.29, 95% CI 1.05-1.58)) within 90 days of primary laparoscopic antireflux surgery 
(Table 9). No such pattern was observed within 90 days of secondary antireflux surgery, and 
there were no statistically significant associations between age, calendar period, sex, hospital 
volume and risk of reoperation within 90 days following both primary laparoscopic and 
secondary antireflux surgery. 
 
Table 9. ORs and 95% CIs of 90-day mortality and 90-day reoperation after primary 





 Cases (n) Adjusted ⱡ OR (95% CI) Cases (n) Adjusted ⱡ OR (95% CI) 
     
Age (in years)    
18-42 6 1.00 (Reference) 241 1.00 (Reference) 
43-55 6 0.87 (0.28-2.73) 245 0.92 (0.78-1.11) 
56-80 23 2.66 (1.03-6.85) 264 0.98 (0.81-1.18) 
     
Sex   
Male 15 1.00 (Reference) 389 1.00 (Reference) 
Female 20 1.08 (0.54-2.14) 361 1.04 (0.89-1.20) 
     
Charlson Comorbidity Index    
0 21 1.00 (Reference) 608 1.00 (Reference) 
1 8 1.93 (0.84-4.44) 117 1.29 (1.05-1.58) 
>2 6 6.25 (2.42-16.14) 25 1.47 (0.97-2.23) 
     
Annual hospital volumeǁ   
<24 13 1.00 (Reference) 252 1.00 (Reference) 
25-47 14 0.99 (0.43-2.25) 224 0.84 (0.70-1.02) 
>47 6 0.58 (0.22-1.57) 252 1.10 (0.91-1.32) 
     
Calendar period (in years)   
2000 – 2003 6 1.00 (Reference) 229 1.00 (Reference) 
2004 – 2008 10 1.51 (0.55-4.20) 246 1.07 (0.89-1.29) 
2009 – 2018 19 2.33 (0.91-5.98) 275 1.15 (0.95-1.38) 
     
* Two or more days longer than the median length of hospital stay after surgery. 
ⱡ Adjusted for age, sex, Charlson Comorbidity Index, calendar period, and country. 





Following primary laparoscopic and secondary antireflux surgery, the median length of 
hospital stay was 3 days (IQR 2-4 days) and 4 days (IQR 2-6 days), respectively. Among 
participants in the primary and secondary antireflux surgery groups, 5,252 (20%) and 477 
(29%) had prolonged hospital stay, respectively. Among participants in the primary 
laparoscopic antireflux surgery group, an increased risk of prolonged hospital stay was seen 
with higher age (upward deflection after 60 years of age), and a decreased risk of prolonged 
hospital stay was seen with greater hospital volume (Figure 5). In the early calendar years of 
the study, an initial decrease in risk of prolonged hospital stay was observed, which remained 
stable over time (Figure 5).  
 
Figure 5. Probability (black line) with 95% CIs (grey area) of prolonged hospital stay by 
hospital volume, age and calendar year after primary laparoscopic antireflux surgery. 
 
The OR of prolonged hospital stay was increased for males compared to females (OR 1.48, 
95% CI 1.37-1.61), and increased with higher Charlson comorbidity score compared to no 
comorbidity (OR 1.54 [95% CI 1.40-1.68] with a score of 1 and OR 2.38 [95% CI 1.98-2.85] 
with a score of ≥2). Similar results were seen in the secondary antireflux surgery group, 






6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study design 
All studies in the present thesis are population-based cohort studies from the Nordic 
countries. Cohort studies comprise individuals from a source population, selected based on 
one or several pre-specified exposures, who are followed over time to assess outcomes of 
interest. A strength of studies I-IV is the population-based design, encompassing essentially 
all individuals who have a documented diagnosis of GERD or antireflux surgery procedure, 
and meeting the inclusion criteria of each study, in any of the five Nordic countries. This 
provided an unselected cohort. A long-term and virtually complete follow-up of all cohort 
participants was made possible by the well-maintained nationwide health data registries, in 
which all individuals are traceable by a personal identity number, uniquely available in the 
Nordic countries. This design abated selection bias, minimized loss to follow-up, and 
provided a large sample size, which is needed to enable assessment of rare outcomes. In 
general, weaknesses to consider in observational studies pertain to internal and external 
validity. The key biases that determine the internal validity of observational studies are 
selection bias, information bias, and confounding. Another source of error is chance (random 
error). 
6.1.2 Internal validity 
6.1.2.1 Selection bias 
Selection bias is a differential error that can occur when selection and inclusion of 
participants in a study result in a systematic difference between the sample population and the 
source population. This can yield study results that cannot be transferred to the source 
population. Lack of participation, or self-selection bias, is not likely to have significantly 
contributed to selection bias in Study I-IV because almost all patients in the five Nordic 
countries were included. Nonetheless, in clinical practice, the likelihood of patients receiving 
a diagnosis of GERD may vary depending on the main cause of seeking healthcare. 
Therefore, participation in Study I-III might have been affected by local traditions of 
hospitals and outpatient clinics. However, this is likely to mainly affect individuals with mild 
GERD. Moreover, local traditions should not affect the documentation of antireflux surgery 
in the national patient registries. Another possible contribution to selection bias is that 
individuals with mild GERD might never be diagnosed because not all patients seek 
healthcare for their GERD-symptoms, or are managed solely in a primary care setting. These 
individuals do not meet the inclusion criteria of Study I-III, i.e. documented diagnosis of 
GERD in the national patient registries. However, this should not have had a strong influence 
on the internal validity of Study I-III, where it was more important that the GERD diagnosis 
was accurate than including more ill-defined GERD diagnoses, which could have introduced 
substantial information bias. 
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6.1.2.2 Information bias 
Information bias occurs when measurements or classifications of one or more exposures or 
outcomes in a study are inaccurate. Differential misclassification occurs when measurement 
errors lead to a misclassification of exposure or outcome that differs between the comparison 
groups. Non-differential misclassification occurs when measurement errors lead to a 
misclassification of exposure or outcome that do not differ between the comparison groups. 
Misclassification of exposures can be considered limited in all studies in the present thesis. 
Nonetheless, in Study I-II, some misclassification of GERD diagnosis is possible in 
participants who received a clinical GERD diagnosis without objective confirmation (by 
endoscopic assessment). However, the sub-analyses of participants with objectively 
determined GERD in these studies showed similar results compared to the main analyses, 
which suggests that misclassification of GERD was limited. Furthermore, Study III was 
restricted to participants with objectively confirmed GERD only. Misclassification of 
antireflux surgery should be low or absent considering the existence of universal health care 
systems, mandatory reporting of surgical procedures, and reimbursement dependent on this 
reporting in the Nordic countries. Recurrence of GERD following antireflux surgery is not 
uncommon, and has been shown to occur in 17.7% of the Swedish cohort participants,(47) 
which could be seen as a kind of exposure misclassification in Study I-III. This 
misclassification could have affected the results toward null values. Misclassification of 
outcomes (malignancy, death date and cause of death) in Study I-IV can also be considered 
low given the high completeness and validity of the national cancer registries and cause of 
death registries in the Nordic countries. 
6.1.2.3 Random error 
Random error, or chance variation, is the divergence of statistical measurements in a sample 
from the true value in the source population, due to chance. This error is the inverse of 
statistical precision. All study populations, including those that are national population-based, 
are considered to be sampled from a super-population. Therefore, random errors cannot be 
entirely avoidable. An effective approach to counteract random error is the use of large 
sample sizes and avoidance of multiple testing. Therefore, the use of a multinational 
population-based cohort in Study I-IV decreased the risk of random errors and increased 
statistical precision. In statistical analyses, common measurements of point estimate precision 
include calculation of CIs or P-values. The CIs are usually set at 95%, which represents a 
95% confidence that the true value in the super population lies within the calculated interval, 
given no influence of any bias. The P-values are usually set at a significance level of <0.05, 
which represents a less than 5% probability of finding a difference between comparison 
groups in a sample population when no true difference exists in the super-population. This is 
commonly referred to as the probability of Type-I error or false rejection of the null 
hypothesis. Type-I errors can be counteracted by reducing significance testing or correcting 
for multiple testing. However, these strategies usually increase the risk of Type-II errors 
(non-rejection of a false null-hypothesis), i.e. observing no difference between comparison 
groups in a sample population when a true difference exists in the super-population. In this 
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thesis, multiple testing was reduced by using limited predefined study hypotheses and only 
including covariates based on subject-matter knowledge. Furthermore, in all studies of the 
present thesis, only 95% CIs were used for assessment of statistical precision and 
significance, which is mostly more informative than P-values because the CIs also provide 
information on strength and direction of effect. 
6.1.2.4 Confounding 
Confounding might occur when a factor is independently associated with both the exposure 
and outcome, and is not a mediator, i.e. not in the causal pathway between the exposure and 
outcome. The presence of confounding is commonly a challenge in observational studies, 
because they are not randomized, and if not sufficiently counteracted, it can account for some 
or all of the associations found in such studies. In observational studies, confounding can be 
counteracted in the study design phase by matching study participants based on variables that 
could introduce confounding, or in the statistical analyses by adjusting or stratifying for such 
variables. The main approach to reduce confounding in the studies of the present thesis was 
by using multivariable regression models, in which adjustments and stratifications were 
made. The covariates selected for inclusion in the models was based on subject-matter 
knowledge. In some cases, direct data on relevant covariates that could introduce 
confounding was not available. These were instead indirectly accounted for by capturing 
proxy indicators, i.e. indicators that are closely related to the possibly confounding covariates. 
Nonetheless, residual or unmeasured confounding is a limitation in each of the studies 
included in the thesis. 
6.1.3 External validity 
External validity, also called generalizability, pertains to the possibility of inferring results 
from a study population to other populations and settings. While internal validity is not 
affected by external validity, it is very difficult to discuss generalization when the internal 
validity is poor. Study I-IV were all multinational and population-based, encompassing 
nationwide participation in the Nordic countries. This should have facilitated high 
generalizability to other Western populations at least. 
6.2 GENERAL DISCUSSION 
6.2.1 Study I 
Study I suggests that the risk of laryngeal and pharyngeal squamous cell carcinoma is 
decreased in patients with GERD who have had antireflux surgery compared to the 
corresponding background population and to patients with GERD who have not undergone 
such surgery.  
Strengths of Study I are the population-based design and the long and complete follow-up of 
a large sample size. Analyses of the sub-cohort of severe GERD (objectively determined) 
decreased risk of misclassification of GERD, and the similar results provided more validity to 
the analyses of the main cohort. Among weaknesses was possible confounding. The main 
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shared risk factors for laryngeal and pharyngeal squamous cell carcinoma, and GERD, are 
tobacco smoking and heavy alcohol consumption, and to a less extent obesity.(3, 143, 144) It 
was not possible to adjust for these factors in the SIR-analyses, but they were controlled for 
in the Cox regression analyses. However, direct information on tobacco smoking and alcohol 
consumption are not available in the national patient registries, but were instead adjusted for 
through proxies, which should have counteracted confounding. Finally, despite the large 
cohort size, the power of the analyses was limited due to low incidence of the tumor types 
under study. 
No other study has assessed the influence of antireflux surgery on the risk of laryngeal or 
pharyngeal cancer. The observed decrease in risk of laryngeal and pharyngeal squamous cell 
carcinoma after antireflux surgery indicates that these tumors can be counteracted in patients 
with GERD. Another explanation could be that individuals who are selected for surgery 
might be less likely to be heavy tobacco smokers or alcohol consumers compared to the 
corresponding background population and to non-operated patients with GERD. Nonetheless, 
these factors were indirectly adjusted for in the analyses. Furthermore, in a recent meta-
analysis, the risk of laryngeal cancer risk was found to be increased by GERD after 
controlling for direct measures of tobacco smoking and alcohol intake.(93) In addition, the 
point estimates of laryngeal squamous cell carcinoma was further decreased over time, 
following antireflux surgery, which is not likely explained by selection to surgery. 
Chronic inflammation and repeated inflammatory insults have been associated with several 
cancer types in the aerodigestive tract,(145-149) and an association between GERD and 
laryngeal and pharyngeal cancer has been suggested in several studies.(88-94) The epithelium 
of larynx and pharynx seems to be vulnerable to repeated inflammatory insults from acidic 
and non-acidic duodeno-gastric contents.(63-67, 93) Therefore, the development of laryngeal 
and pharyngeal cancer might be counteracted by means of the mechanic and physiologic 
barrier that is created with antireflux surgery, which hinders both acidic and non-acidic 
refluxate, in contrast to antireflux medication, which only reduces the acidic component of 
refluxate.(25) The finding of no association between GERD and laryngeal and pharyngeal 
squamous cell carcinoma in Study I was not expected. An explanation could be that 
antireflux medication had some cancer-preventive effects, which is typically used in non-
operated patients with GERD. Another explanation could be that compared to the background 
population, those who are diagnosed with GERD are more prone to reduce tobacco smoking 
and alcohol intake.  
6.2.2 Study II 
Study II suggests that compared to the corresponding background population and non-
operated patients with GERD, patients with GERD who have undergone antireflux surgery 
have a decreased risk of small cell carcinoma and squamous cell carcinoma, but not of 
adenocarcinoma of the lung. 
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The methodological strengths of Study II include the large sample size, population-based 
design, and the long and complete follow-up. The similarity in the results of the main and 
sub-cohort suggests that misclassification of GERD was low. Among weaknesses is possible 
confounding. The main shared risk factor for the lung cancer tumor types and GERD is 
tobacco smoking.(3, 150) While direct data on tobacco smoking was not available, 
adjustment for chronic obstructive pulmonary disease was performed, which has a strong 
association to duration of smoking and intensity.(151) Furthermore, in a study assessing 
esophageal adenocarcinoma, using the same cohort as in Study II, antireflux surgery did not 
influence the risk, which indicates that selection of patients with GERD to surgery introduces 
limited bias compared to the non-operated group and the background population.(87) The 
findings of this study could be generalized to other Western populations, where the 
prevalence of GERD is similar.(4, 5)  
No previous study has assessed the risk of lung cancer following antireflux surgery in 
patients with GERD. The findings suggest that antireflux surgery decreases the risk of small 
cell carcinoma and squamous cell carcinoma. Because no further decrease in risk could be 
observed over time after antireflux surgery, careful interpretation of the results is necessary. 
The lack of risk reduction over time could nonetheless be explained by recurrence of GERD 
after surgery. Future studies are required to confirm these findings. Nevertheless, a possible 
biologic explanation to these findings is that antireflux surgery mechanically hinders acidic 
and non-acidic duodeno-gastric reflux, which leads to a reduction of micro-aspiration, 
repeated inflammatory insults, and subsequent oncogenic processes in tissues of the lung. 
Since antireflux medication does not hinder proximal reflux, but only reduces its acidity, the 
finding of a decreased risk of lung cancer following antireflux surgery compared to non-
operated patients with GERD (vastly using antireflux medication) was expected.  
A possible explanation for the findings of a reduction in risk for small cell carcinoma and 
squamous cell carcinoma, but not of adenocarcinoma, after antireflux surgery could be due to 
anatomical differences of the histologic types. Small cell carcinoma and squamous cell 
carcinoma mainly arise in the central airways, while adenocarcinoma primarily arise in the 
peripheral airways, which is further away from possible micro-aspirations. 
6.2.3 Study III 
Study III indicates that in patients with reflux esophagitis or Barrett’s esophagus, antireflux 
surgery decreases mortality from all causes, cardiovascular disease, respiratory disease, 
laryngeal or pharyngeal cancer, and lung cancer, but not from esophageal cancer, compared 
to antireflux medication. 
Among methodological strengths are again the population-based design, large sample size, 
and long and complete follow-up. Misclassification of GERD was counteracted by only 
including patients with objectively identified GERD, i.e. reflux esophagitis and Barrett’s 
esophagus. Among weaknesses is confounding. Compared to non-operated patients with 
GERD, patients selected for antireflux surgery might have been more fit, less obese, and have 
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less comorbidity and tendency of being heavy smokers or alcohol consumers. To counteract 
this, adjustment for Charlson Comorbidity Index was performed for diagnoses closely related 
to obesity, tobacco smoking and heavy alcohol consumption, such as diabetes type II, chronic 
obstructive pulmonary disease and liver disease.(151-153) Furthermore, the analyses 
restricted to patients with Charlson Comorbidity Index score of 0 also showed a decreased 
mortality. Confounding was also assessed in a sensitivity analysis of colon cancer risk in 
patients with GERD, a cancer type that is not associated with GERD or its treatment. 
Compared to the antireflux medication group, the analyses showed no reduction in risk of 
colon cancer in the antireflux surgery group (HR 1.16, 95% CI 1.01-1.33). The limited 
availability of data on antireflux medication is another limitation. However, virtually all non-
operated participants with reflux esophagitis or Barrett’s esophagus included in the large 
validation study were shown to be using antireflux medication, which also reflects practice 
guidelines.(27) 
The few previous studies assessing antireflux surgery’s influence on survival in patients with 
GERD have shown conflicting results. .(57, 58) These studies were smaller in sample size 
and had shorter follow-up. The finding of lower mortality after antireflux surgery could be 
due to antireflux surgery creating a barrier that counteract both acidic and non-acidic reflux, 
which might reduce the risk of extra-esophageal diseases that may influence survival, and are 
associated with GERD, i.e. idiopathic pulmonary fibrosis, asthma, and chronic obstructive 
pulmonary disease.(60, 68, 154, 155) An alternative explanation of patient selection, as 
discussed above, cannot be entirely ruled out. Healthy and fit individuals who require a less 
technically demanding antireflux surgery are likely to be selected for laparoscopic rather than 
open surgery. This might explain the finding of a more pronounced decrease in mortality in 
patients who underwent laparoscopic antireflux surgery, compared to open surgery. A recent 
multinational population-based study (from our group) showed no decreased risk in 
esophageal adenocarcinoma after antireflux surgery, which supports this study’s finding that 
antireflux surgery does not influence mortality from esophageal cancer.(87) Furthermore, 
Study I of this thesis suggests that antireflux surgery might decrease the risk of laryngeal and 
pharyngeal squamous cell carcinoma, which is in line with this study’s finding that antireflux 
surgery decreases mortality from these tumors.  
6.2.4 Study IV 
Study IV found low 90-day mortality and reoperation rates, as well as a short median hospital 
stay following primary elective laparoscopic and secondary antireflux surgery. For 
laparoscopic antireflux surgery, the risk of 90-day mortality increased with comorbidity, 
higher age, and lower annual hospital volume, and the risk of 90-day reoperation increased 
with comorbidity, while the risk of prolonged hospital volume increased with comorbidity 
and higher age, and decreased with male sex, higher hospital volume, and later calendar 
period. For secondary antireflux surgery, the risk of prolonged hospital stay was increased by 
comorbidity and higher age, and decreased with later calendar periods. 
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Among the strengths of this study is the multinational population-based design and complete 
follow-up of participants, encompassing virtually all individuals who have had primary 
laparoscopic or secondary antireflux surgery during the study period. Weaknesses include 
residual or unmeasured confounding. Higher BMI and tobacco smoking can lead to increased 
risk of postoperative complications. These factors were only indirectly accounted for with the 
adjustment of Charlson Comorbidity Index. Furthermore, although the sample size was large, 
the power of some sub-analyses was low. 
The absolute rate of all-cause 90-day mortality after primary laparoscopic and secondary 
antireflux surgery was similar to some other studies.(35, 50) To our knowledge, no previous 
study has explored risk factors of short-term postoperative mortality following antireflux 
surgery, which is likely because of the low 90-day mortality rates. Higher age (above 60 
years) and comorbidity increased the risk of 90-day mortality following primary laparoscopic 
antireflux surgery, while higher hospital volume possibly decreased that risk. The higher 
frailty and probability of severe postoperative complications in older and comorbid patients, 
and the greater experience in peri- and postoperative care in high volume centers may explain 
these associations. This could also explain the findings that higher age and comorbidity 
increased the risk of prolonged hospital stay and high-volume hospitals decreased that risk, 
following primary laparoscopic and secondary antireflux surgery.  
6.3 IMPLICATIONS AND FUTURE RESEARCH 
The risk of laryngeal, pharyngeal, and lung cancer following antireflux surgery has not been 
previously studied. Therefore, the findings of a reduced risk in laryngeal and pharyngeal 
squamous cell carcinoma, and in small cell and squamous cell carcinoma of the lung require 
confirmation in future studies before any clinical recommendations can be made. 
Furthermore, in view of the low incidence of laryngeal and pharyngeal cancer,43 this thesis 
does not suggest recommendation of antireflux surgery for only cancer protective reasons. 
However, these findings indicate that antireflux surgery is effective in the treatment of more 
proximal reflux and regurgitation, and contribute to tumor etiology knowledge. 
Considering the scarcity of studies that have investigated mortality in patients with GERD 
who have undergone antireflux surgery, compared to antireflux medication, further 
investigation is needed to confirm the findings of reduced mortality in those operated, before 
any clinical recommendations can be made. 
Finally, this thesis has demonstrated that antireflux surgery has a favorable safety profile. 
Nonetheless, while severe complications are rare, they do exist. Reduction of poor short-term 
outcomes after primary laparoscopic and secondary antireflux surgery is likely accomplished 
by selection of patients below 60 years of age, without severe comorbidity, and by 






 In patients with GERD, antireflux surgery might decrease the risk of laryngeal 
squamous cell carcinoma, and possibly also pharyngeal squamous cell carcinoma. 
 Antireflux surgery for GERD seems to reduce the risk of small cell carcinoma and 
squamous cell carcinoma, but not of adenocarcinoma of the lung. 
 In patients with GERD, antireflux surgery compared to antireflux medication seems 
to decrease the risk of all-cause mortality and mortality from cardiovascular disease, 
respiratory disease, laryngeal or pharyngeal cancer, and lung cancer, but not from 
esophageal cancer. 
 Primary laparoscopic antireflux surgery and secondary antireflux surgery is an overall 




8 POPULAR SCIENCE SUMMARIES 
8.1 POPULAR SCIENCE SUMMARY 
8.1.1 Background 
Gastroesophageal reflux disease (GERD) is a common condition affecting up to 28% of 
adults in the Western world and the Middle East, and up to 8% of adults in Asia. It is caused 
by a dysfunction in the anatomic components surrounding the junction between the stomach 
and the gullet (esophagus), which causes the content of the stomach to leak through the 
junction and up into the esophagus, leading to heartburn and regurgitation. GERD is a benign 
condition, but can sometimes lead to complications such as inflammation in the esophagus 
and cellular changes in the mucosa of the esophagus (called Barrett’s esophagus) that in rare 
cases can lead to esophageal cancer. Some studies have shown that GERD could also 
increase the risk of cancer in the larynx, pharynx, and lung, with the proposed mechanism 
that the stomach content affects these organs by reaching further up, above the esophagus. To 
treat GERD, antireflux medication is used, mainly proton pump inhibitors (PPI), but an 
alternative is antireflux surgery. While PPIs act by reducing the acidity of stomach content, 
antireflux surgery mechanically hinders GERD. The surgical procedure is performed by 
wrapping a part of the upper stomach around the lower part of the esophagus, thus reducing 
reflux by tightening the upper orifice of the stomach. No previous studies have investigated 
whether antireflux surgery reduces the risk of cancer in the larynx, pharynx or lung, and the 
literature is sparse on whether antireflux surgery, compared to antireflux medication, 
improves the survival in patients with GERD. 
8.1.2 Methods and results 
The four studies of this thesis were based on the Nordic antireflux surgery cohort 
(NordASCo), which includes adult individuals who have a registered diagnosis of GERD or 
antireflux surgery procedure in the national patient registries of Denmark, Finland, Iceland, 
Norway or Sweden, in the years 1980 to 2018. NordASCo also includes information from the 
national cancer registries and the national cause of death registries. 
Study I aimed to assess whether antireflux surgery decreases the risk of cancer in the larynx 
or pharynx of the most common type, i.e. squamous cell carcinoma and Study II examined 
the risk of different types of lung cancer in patients with GERD. Compared to the background 
population of the corresponding age sex and calendar year, those who underwent antireflux 
surgery had an overall decreased risk of laryngeal and pharyngeal squamous cell carcinoma. 
The risk was further decreased over time in laryngeal squamous cell carcinoma. The risk of 
small cell and squamous cell carcinoma of the lung was also decreased after antireflux 
surgery, but no such decrease was found for adenocarcinoma of the lung. The results of the 
comparison between operated and non-operated patients with GERD showed very similar 
risk patterns to those described above (both studies). 
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Study III aimed to investigate whether antireflux surgery influences long-term mortality from 
any cause, and from causes related to specific diseases. Mortality risk was assessed 
comparing antireflux surgery with antireflux medication treatment in patients with GERD. 
The results showed that patients who had undergone antireflux surgery had decreased 
mortality from any cause, and from cardiovascular disease, respiratory disease, laryngeal or 
pharyngeal cancer, and lung cancer, but not from esophageal cancer. 
Study IV aimed to assess absolute risk and risk factors of death and reoperation due to 
postoperative complications shortly after (within 90 days) primary laparoscopic antireflux 
surgery and secondary antireflux surgery, as well as risk and risk factors of prolonged 
hospital stay. Assessment of primary laparoscopic antireflux surgery included patients with 
GERD who underwent their first antireflux surgery procedure, and secondary antireflux 
surgery included those who had previously undergone antireflux surgery and underwent a 
second operation. This study included adult patients in NordASCo who had undergone 
antireflux surgery from 2000 to 2018. The study showed a low risk of death (0.13%) and 
reoperation (3.0%) within 90 days of primary surgery, and a low risk of death (0.19%) and 
reoperation (6.2%) within 90 days of secondary surgery. The risk of 90-day mortality 
increased in patients with higher age (particularly in those above 60 years) and with other 
diseases (comorbidity), and the risk seemed to decrease in those who underwent surgery in 
specialized centers with high operation volume. The risk of reoperation within 90 days of 
both primary and secondary surgery increased in patients with greater comorbidity. Patients 
with higher age and greater comorbidity had an increased risk of prolonged hospital stay after 
both primary and secondary surgery, and those who underwent primary surgery at specialized 
high-volume centers had a reduced risk. 
8.1.3 Summary 
In summary, antireflux surgery is a safe treatment option in the treatment of GERD. This 
surgery seems to reduce the risk of laryngeal and pharyngeal squamous cell carcinoma, and 
small cell carcinoma and squamous cell carcinoma of the lung, and also decrease mortality in 




8.2 POPULÄRVETENSKAPLIG SAMMANFATTNING 
8.2.1 Bakgrund 
Gastroesofageal refluxsjukdom (reflux) finns hos uppemot 28% av den vuxna befolkningen i 
västvärlden och Mellanöstern, och uppemot 8% av vuxna befolkningen i Asien. Reflux 
orsakas av nedsatt funktion i vävnaderna runt övergången mellan magsäck och matstrupe, 
vilket orsakar ett ökat läckage av surt magsäcksinnehåll upp i matstrupen och leder till 
halsbränna och uppstötningar. Reflux är en godartad sjukdom, men kan ibland leda till 
komplikationer såsom inflammation i matstrupen och cellförändringar i matstrupen (kallade 
Barretts esofagus) som i sällsynta fall kan leda till matstrupscancer. Vissa studier har visat att 
reflux även möjligen kan öka risken för cancer i svalg, struphuvud och lunga. Föreslagen 
verkningsmekanism är att magsäcksinnehållet påverkar dessa organ genom att nå högre upp, 
ovanför matstrupen. Reflux behandlas främst med läkemedel, vanligen med 
protonpumpshämmare, men ett alternativ är operation med så kallad antirefluxkirurgi. Medan 
protonpumpshämmare verkar genom att sänka surhetsgraden i magsäcksinnehållet, motverkar 
antirefluxkirurgi reflux mekaniskt. Operationen utförs genom att övre delen av magsäcken 
fästs runt matstrupens nedre del, vilket medför en åtstramning av magsäcksmunnen med 
minskad reflux som följd. Inga tidigare studier har undersökt om antirefluxkirurgi minskar 
risken för cancer i svalg, struphuvud eller lunga, och få studier har utvärderat om 
antirefluxkirurgi påverkar överlevnaden hos patienter med reflux, jämfört med om de 
behandlas med läkemedel. 
8.2.2 Metoder och resultat 
De fyra studierna i denna avhandling har baserats på en nordisk kohort (Nordic antireflux 
surgery cohort – NordASCo) som består av individer med registrerad refluxdiagnos eller som 
genomgått antirefluxkirurgi enligt de nationella patientregistren i Danmark, Finland, Island, 
Norge eller Sverige från år 1980 till 2018. NordASCo innehåller även data från de nationella 
cancerregistren och dödsorsaksregistren. 
Studie 1 undersökte om antirefluxkirurgi minskar risken för cancer (av den dominerande 
typen skivepitelcancer) i svalg eller struphuvud, medan studie 2 undersökta detta för olika 
cancertyper i lungan bland patienter med reflux. Jämfört med bakgrundsbefolkningen av 
motsvarande ålder, kön och kalenderår hade de som genomgått antirefluxkirurgi en minskad 
risk för skivepitelcancer i svalg och struphuvud, samt för småcellig cancer och 
skivepitelcancer i lungan, men inte för adenocarcinom i lungan. Resultaten var snarlika i 
jämförelsen av opererade med icke-opererade patienter med reflux i båda studierna. 
Studie 3 utvärderade om antirefluxkirurgi påverkar total dödlighet och sjukdomsspecifik 
dödlighet. Risken för död jämfördes mellan opererade och icke-opererade patienter med 
reflux. Resultaten visade att patienter som opererats hade en minskad total dödlighet samt 
minskad dödlighet i hjärt-kärlsjukdomar, sjukdomar i andningsvägarna, samt cancer i svalg, 
struphuvud och lunga. Däremot förelåg ingen minskad dödlighet i matstrupscancer. 
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Studie 4 undersökte risk och riskfaktorer för död och behov av omoperation pga. 
komplikationer inom 90 dagar efter primär (första gången) antirefluxkirurgi med 
titthålsteknik och sekundär (andra gången) antirefluxkirurgi, och även risken för förlängd 
sjukhusvistelse efter dessa ingrepp. Studien inkluderade vuxna patienter som hade genomgått 
antirefluxkirurgi från år 2000 till 2018 i NordASCo. Studien fann en låg risk för död (0,13%) 
och reoperation (3,0%) inom 90 dagar efter primär kirurgi, och likaså en låg risk för död 
(0,19%) och reoperation (6,2%) inom 90 dagar efter sekundär kirurgi. Inom 90 dagar efter 
primär kirurgi ökade dödsrisken bland patienter med högre ålder (särskilt vid över 60 års 
ålder) samt med samsjuklighet, och dödsrisken verkade minska bland de som opererades på 
sjukhus med hög operationsvolym. Reoperationsrisken inom 90 dagar efter primär och 
sekundär kirurgi ökade bland patienter med samsjuklighet. Patienter med högre ålder och mer 
samsjuklighet hade ökad risk för förlängd sjukhusvistelse efter både primär och sekundär 
kirurgi, och de som genomgick primär kirurgi på sjukhus med högre operationsvolym hade 
en minskad sådan risk.  
8.2.3 Sammanfattning 
Sammanfattningsvis är antirefluxkirurgi ett tryggt behandlingsalternativ för reflux. Denna 
kirurgi verkar minska risk för skivepitelcancer i svalg och struphuvud, samt för småcellig 





 الملخص العلمي اليسير 8.3
 تمهيد 8.3.1
% من البالغين في العالم الغربي وفي الشرق28حالة مألوفة حيث يعاني حوالي  يشكل اإلرجاع المعدي المريئي (القلس)  
% من البالغين في آسيا. ويتسبب القلس عن خلل وظيفي في البنية التشريحية النسيجية الواصلة بين8األوسط، وحوالي   
 المعدة والمريء، مما يسبب تسرب محتويات المعدة صعوداً إلى المريء مؤدياً الى الشعور بحرقة في المعدة والقلس
اً الى مضاعفات مثل التهاب المريء، أو تغيرات نسيجية (مريء باريت)يعتبر القلس مرضاً حميداً، ولكنه قد يؤدي أحيان   
 ونادراً مايؤدي الى سرطان المريء. تظهر بعض الدراسات ان القلس يمكن أن يؤدي إلى زيادة خطر اإلصابة بسرطان
هذه األعضاء عندالحنجرة، البلعوم، والرئه، واآللية المفترحة لزيادة هذا الخطر هي أن محتويات المعدة تؤثر على   
 صعودها الى أعلى من ارتفاع المريء
 لمعالجة القلس تستخدم عادة مضادات الحموضة وخاصة مثبطات مضحة البروتون (م م ب) التي تقلل من حموضة
 محتويات المعدة، وتعتبر الجراحة المضادة للقلس خياراً آخر يهدف الى تصحيح اإلختالل الوظيفي الذى أدى الى القلس
جراء الجراحة بلف جزء من المعدة حول الجزء السفلي من المريء، وبذا يقل اإلرتجاع المعدي المريئي حيث تم احكاميتم إ  
 الفتحة العلوية للمعده. ليست هناك دراسات الستقصاء ما إذا قللت الجراحة المضادة للقلس من خطر اإلصابة بسرطان
ية بين المعالجة الدوائية والجراحة المضادة للقلس من حيث الوفيات بينالحنجرة، البلعوم أو الرئه، وتقارن النشرة الحال  
 المرضى
 طريقة البحث والنتائج 8.3.2
 تعتمد الدراسات في هذه األطروحة على ىسجالت مجموعة دول الشمال للجراحة المضادة للقلس، شاملة كافة المرضى
المضادة للقلس في سجالت الدانمارك، فنلندا، ايسلندا البالغين الذين تم تشخيصهم كمرضى بالقلس أو تم تسجيلهم للجراحة  
. تتضمن هذه السجالت معلومات من السجالت الوطنية للسرطان وكذلك2014 – 1980األعوام   النرويج والسويد خالل  
 سجالت أسباب الوفيات
لبلعوم أو الرئه في مرضىهدفت الدراسة األولى والثانية إلى تقييم مدى اإلقالل من خطر اإلصابة بسرطان الحنجرةـ ا  
 القلس مستخدمة سجالت مجموعة دول الشمال للجراحة المضادة للقلس. بالمقارنة مع مجموعة المقارنة فقد انخفضت في
 المرضى الذين خضعوا للجراحة نسبة خطر حدوث سرطان الحنجرة والبلعوم و سرطان الخاليا الصغيرة وسرطان الخاليا
يس في السرطان الغدي للرئه. وازداد اإلنخفاض مع مرور الوقت في سرطان الحنجرة. وعندولكن ل  الحرشفية في الرئة  
 المقارنة بين من عولجوا جراحيا ومن عولجوا دوائياً تبين عدم وجود فارق في نسبة الخطر في كل أنواع السرطان
لقلس إلى معرفة ما إذا كان للجراحةهدفت الدراسة الثالثة معتمدة على سجالت مجموعة دول الشمال للجراحة المضادة ل   
 المضادة للقلس تأثير على الوفيات (على المدى الطويل) لكل األسباب وألسباب تتعلق بأمراض معينة، تم تقييم خطر الوفاة
 بين مرضى القلس الذين تمت معالجتهم دوائياً والذين عولجوا جراحياً. وأظهرت النتائج أن المعالجة الجراحية أدت الى
سرطان الحنجرة  خفاض معدل الوفيات بكل األسباب، وبسبب أمراض القلب واألوعية وأمراض الجهاز التنفسي، وبسببأن  
 أو البلعوم ، وسرطان الرئة ، ولكن ليس في معدل الوفيات بسبب سرطان المريء
إجراء الجراحة بسببأما الدراسة الرابعة فقد هدفت إلى تقصي الخطر المطلق وعوامل الخطورة للوفاة وإلعادة   
يوماً من الجراحة األولية الجزء السفلي من المريء بالمنظار والجراحة الثانوية، باإلضافة إلى نسبة 90المضاعفات خالل   
 الخطر وعوامل الخطورة بسبب البقاء المطول في المستشفى بعد هذه العمليات الجراحية
ن يعانون من القلس ممن خضعوا ألول عملية جراحية، وأولئك الذينشمل تقييم الجراحة األولية بالمنظار المرضى الذي   
 خضعوا لجراحة ثانوية بما في ذلك من خضعوا سابقاً لعملية جراحية مضادة للقلس و خضعوا أيضاً لعملية ثانية
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المرضىاستندت هذه الدراسة إلى نسخة محدثة من سجالت مجموعة دول الشمال للجراحة المضادة للقلس ، بما في ذلك   
في الدول الشمال الخمس. أظهرت الدراسة 2018إلى  2000البالغين الذين خضعوا لجراحة مضادة للقلس بين العام   
يوًما من الجراحة األولية ، كذلك انخفاض خطر الوفاة 90٪) خالل 3.0٪) وإعادة الجراحة (0.13انخفاض خطر الوفاة (  
وًما من الجراحة الثانويةي 90٪) في غضون 6.2وإعادة الجراحة ( (0.19٪)  
عاماً  60يوماً م الجراحة األولية ازداد خطر الوفاة في المرضى كبار السن خاصة الذين تزيد أعمارهم عن  90خالل   
 ولديهم أمراض مترافقة. ويبدو أن نسبة الخطر تدنت في المرضى الذين خضعوا للجراحة في مراكز متخصصة ذات كم
 كبير من الجراحات
يوماً تلت الجراحة األولية والثانوية في المرضى ذوي األمراض المترافقة 90اد خطر اعادة الجراحة خالل كذلك ازد   
 وختاماً فان خطرإقامة المرضى كبار السن ذوو األمراض المرافقة في المستشفى قد ازداد بعد الجراحة األولية والثانوية وقد
لمراكز المتخصصة ذات الكم الكبير من الجراحاتتدنى الخطر في المرضى الذين خضعوا للجراحة في ا  
 الخالصة  8.3.3
 نشكل الجراحة خياراً آمناً في معالجة القلس. ويبدو أن هذه الجراحة تقلل من خطر اإلصابة بسرطان الحنجرة والبلعوم
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Supplementary Table 1. Codes defining participants with gastroesophageal reflux disease 
(GERD), severe GERD (reflux esophagitis or Barrett’s esophagus) and antireflux surgery  
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